Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Scott M. Lippman, Phyllis J. Goodman, Eric A. Klein, Howard L. Parnes, Ian M. Thompson, Alan R. Kristal, Regina M. Santella, Jeffrey L. Probstfield, Carol M. Moinpour, Demetrius Albanes, Philip R. Taylor, Lori M. Minasian, Ashraful Hoque, Sarah Moody Thomas, John J. Crowley, J. Michael Gaziano, Janet L. Stanford, Elise D. Cook, Neil E. Fleshner, Michael M. LieberPhilip J. Walther, Fadlo R. Khuri, Daniel D. Karp, Gary G. Schwartz, Leslie G. Ford, Charles A. Coltman

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.

Original languageEnglish (US)
Pages (from-to)94-102
Number of pages9
JournalJournal of the National Cancer Institute
Volume97
Issue number2
DOIs
StatePublished - Jan 19 2005

Fingerprint

Selenium
Vitamin E
Prostatic Neoplasms
Neoplasms
African Americans
Placebos
Selenomethionine
Puerto Rico
alpha-Tocopherol
Standard of Care
Early Detection of Cancer
Canada
Randomized Controlled Trials
Research Personnel
Health
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lippman, S. M., Goodman, P. J., Klein, E. A., Parnes, H. L., Thompson, I. M., Kristal, A. R., ... Coltman, C. A. (2005). Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute, 97(2), 94-102. https://doi.org/10.1093/jnci/dji009

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). / Lippman, Scott M.; Goodman, Phyllis J.; Klein, Eric A.; Parnes, Howard L.; Thompson, Ian M.; Kristal, Alan R.; Santella, Regina M.; Probstfield, Jeffrey L.; Moinpour, Carol M.; Albanes, Demetrius; Taylor, Philip R.; Minasian, Lori M.; Hoque, Ashraful; Thomas, Sarah Moody; Crowley, John J.; Gaziano, J. Michael; Stanford, Janet L.; Cook, Elise D.; Fleshner, Neil E.; Lieber, Michael M.; Walther, Philip J.; Khuri, Fadlo R.; Karp, Daniel D.; Schwartz, Gary G.; Ford, Leslie G.; Coltman, Charles A.

In: Journal of the National Cancer Institute, Vol. 97, No. 2, 19.01.2005, p. 94-102.

Research output: Contribution to journalArticle

Lippman, SM, Goodman, PJ, Klein, EA, Parnes, HL, Thompson, IM, Kristal, AR, Santella, RM, Probstfield, JL, Moinpour, CM, Albanes, D, Taylor, PR, Minasian, LM, Hoque, A, Thomas, SM, Crowley, JJ, Gaziano, JM, Stanford, JL, Cook, ED, Fleshner, NE, Lieber, MM, Walther, PJ, Khuri, FR, Karp, DD, Schwartz, GG, Ford, LG & Coltman, CA 2005, 'Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)', Journal of the National Cancer Institute, vol. 97, no. 2, pp. 94-102. https://doi.org/10.1093/jnci/dji009
Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal AR et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute. 2005 Jan 19;97(2):94-102. https://doi.org/10.1093/jnci/dji009
Lippman, Scott M. ; Goodman, Phyllis J. ; Klein, Eric A. ; Parnes, Howard L. ; Thompson, Ian M. ; Kristal, Alan R. ; Santella, Regina M. ; Probstfield, Jeffrey L. ; Moinpour, Carol M. ; Albanes, Demetrius ; Taylor, Philip R. ; Minasian, Lori M. ; Hoque, Ashraful ; Thomas, Sarah Moody ; Crowley, John J. ; Gaziano, J. Michael ; Stanford, Janet L. ; Cook, Elise D. ; Fleshner, Neil E. ; Lieber, Michael M. ; Walther, Philip J. ; Khuri, Fadlo R. ; Karp, Daniel D. ; Schwartz, Gary G. ; Ford, Leslie G. ; Coltman, Charles A. / Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). In: Journal of the National Cancer Institute. 2005 ; Vol. 97, No. 2. pp. 94-102.
@article{6c2c409ef2774853981b77d514c2ddb9,
title = "Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)",
abstract = "Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.",
author = "Lippman, {Scott M.} and Goodman, {Phyllis J.} and Klein, {Eric A.} and Parnes, {Howard L.} and Thompson, {Ian M.} and Kristal, {Alan R.} and Santella, {Regina M.} and Probstfield, {Jeffrey L.} and Moinpour, {Carol M.} and Demetrius Albanes and Taylor, {Philip R.} and Minasian, {Lori M.} and Ashraful Hoque and Thomas, {Sarah Moody} and Crowley, {John J.} and Gaziano, {J. Michael} and Stanford, {Janet L.} and Cook, {Elise D.} and Fleshner, {Neil E.} and Lieber, {Michael M.} and Walther, {Philip J.} and Khuri, {Fadlo R.} and Karp, {Daniel D.} and Schwartz, {Gary G.} and Ford, {Leslie G.} and Coltman, {Charles A.}",
year = "2005",
month = "1",
day = "19",
doi = "10.1093/jnci/dji009",
language = "English (US)",
volume = "97",
pages = "94--102",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

AU - Lippman, Scott M.

AU - Goodman, Phyllis J.

AU - Klein, Eric A.

AU - Parnes, Howard L.

AU - Thompson, Ian M.

AU - Kristal, Alan R.

AU - Santella, Regina M.

AU - Probstfield, Jeffrey L.

AU - Moinpour, Carol M.

AU - Albanes, Demetrius

AU - Taylor, Philip R.

AU - Minasian, Lori M.

AU - Hoque, Ashraful

AU - Thomas, Sarah Moody

AU - Crowley, John J.

AU - Gaziano, J. Michael

AU - Stanford, Janet L.

AU - Cook, Elise D.

AU - Fleshner, Neil E.

AU - Lieber, Michael M.

AU - Walther, Philip J.

AU - Khuri, Fadlo R.

AU - Karp, Daniel D.

AU - Schwartz, Gary G.

AU - Ford, Leslie G.

AU - Coltman, Charles A.

PY - 2005/1/19

Y1 - 2005/1/19

N2 - Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.

AB - Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.

UR - http://www.scopus.com/inward/record.url?scp=13744264090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13744264090&partnerID=8YFLogxK

U2 - 10.1093/jnci/dji009

DO - 10.1093/jnci/dji009

M3 - Article

C2 - 15657339

AN - SCOPUS:13744264090

VL - 97

SP - 94

EP - 102

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -